ClinicalTrials.gg
CompletedNCT01474512UNCOVER-1Updated Oct 3, 2019Results posted

A Phase 3 Study in Participants With Moderate to Severe Psoriasis

A Phase 3 interventional study of 80 mg Ixekizumab Dosing Regimens 1, 2, and 3 and Placebo in Psoriasis, sponsored by Eli Lilly and Company. Completed at 104 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-03.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,296
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies testing ixekizumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. ixekizumab · Psoriasis.

Enrollment
2nd of 22
1,296 · median 156
Started
2011
the only one that year
Phase 3
11 of 22
none open now
Registered
2nd of 22
by date
Lead sponsor
16 of 22
Eli Lilly and Company

Among the 22 studies testing ixekizumab in Psoriasis, this one is the 2nd largest by enrollment, is the only one that started in 2011, is one of 11 in phase 3, and was the 2nd registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 22 studies testing ixekizumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About ixekizumab

ixekizumab: first FDA approval 2016 (TALTZ), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing ixekizumab in Psoriasis, or all of them as a file.
02

Study summary

This study will assess the safety and efficacy of LY2439821 compared to placebo in participants with moderate to severe, chronic plaque psoriasis.

03

Conditions studied

  • Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Present with chronic plaque psoriasis based on a confirmed diagnosis of chronic psoriasis vulgaris for at least 6 months prior to randomization
  • At least 10% Body Surface Area (BSA) of Psoriasis at screening and at randomization
  • Static Physician Global Assessment (sPGA) score of at least 3 and Psoriasis Area and Severity Index (PASI) score of at least 12 at screening and at randomization
  • Candidate for phototherapy and/or systemic therapy
  • Men must agree to use a reliable method of during the study
  • Women must agree to use birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment

Exclusion criteria

Exclusion Criteria:

  • Pustular, erythrodermic, and/or guttate forms of psoriasis
  • History of drug-induced psoriasis
  • flare of psoriasis during the 12 weeks prior to randomization
  • Concurrent or recent use of any biologic agent
  • Received systemic psoriasis therapy [such as psoralen and ultraviolet A (PUVA) light therapy] or phototherapy within the previous 4 weeks; or had topical psoriasis treatment within the previous 2 weeks prior to randomization
  • Cannot avoid excessive sun exposure or use of tanning booths for at least 4 weeks prior to randomization and during the study
  • Have participated in any study with interleukin (IL)-17 antagonists, including LY2439821
  • Serious disorder or illness other than plaque psoriasis
  • Serious infection within the last 3 months
  • Breastfeeding or nursing (lactating) women.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,296 participants (actual)

Study arms

  • Experimental
    80 milligrams (mg) Ixekizumab Dosing Regimen 1 (Q2W)

    Administered as two 80-mg subcutaneous (SC) injections at Week 0, then one 80-mg SC injection per Dosing Regimen 1 \[every 2 weeks (Q2W)\] up to and including Week 10. At Week 12, arm is re-randomized to placebo, Dosing Regimen 2 \[every 4 weeks (Q4W)\] or Dosing Regimen 3 \[every 12 weeks Q12W)\].

    Drug: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3

  • Experimental
    80 mg Ixekizumab Dosing Regimen 2 (Q4W)

    Administered as two 80-mg SC injections at Week 0, then one 80-mg SC injection per Dosing Regimen 2 (Q4W) up to and including Week 10. At Week 12, arm is re-randomized to placebo, Dosing Regimen 2 (Q4W) or Dosing Regimen 3 (Q12W).

    Drug: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3

  • Experimental
    80 mg Ixekizumab Dosing Regimen 3 (Q12W)

    Dosing Regimen 3 (Q12W) is not used until Week 12. At Week 12, participants who were re-randomized to this arm were administered one 80-mg SC injection Q12W.

    Drug: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3

  • Placebo comparator
    Placebo

    Administered as 2 SC injections at Week 0, then 1 SC injection per Dosing Regimen 1 (Q2W) up to and including Week 10. At Week 12, arm is re-randomized to placebo or Dosing Regimen 2 (Q4W).

    Drug: Placebo

Interventions

  • Drug80 mg Ixekizumab Dosing Regimens 1, 2, and 3

    Drug page: Ixekizumab

    Administered SC

    Also known as: LY2439821

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Static Physician Global Assessment (sPGA) of 0 or 1 (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Ps Measure: sPGA)

    The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of "0" or "1" with at least a 2-point improvement from baseline.

    Time frame: Week 12

  2. Percentage of Participants Achieving ≥75% Improvement in Ps Area and Severity Index (PASI75) (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Psoriasis Measure: PASI)

    The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease). Participants achieving PASI75 were defined as having an improvement of ≥75% in the PASI score compared to baseline.

    Time frame: Week 12

Secondary outcomes

  1. Percentage of Participants Achieving an sPGA of 0 (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Ps Measure: sPGA)

    The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe).

    Time frame: Week 12

  2. Percentage of Participants Achieving PASI 90% (PASI90) or 100% (PASI100) (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Ps Measure: PASI)

    The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease). Participants achieving PASI90 or PASI100 were defined as having an improvement of ≥90% or of 100% respectively in PASI scores compared to baseline.

    Time frame: Week 12

  3. Percentage of Participants Maintaining sPGA 0 or 1 After Re-Randomization at Start of Maintenance Dosing Period

    The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe).

    Time frame: Week 60

  4. Percentage of Participants With Itch Numeric Rating Scale (Itch NRS) Score ≥4 Point Reduction From Baseline

    The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 (no itch) and 10 (worst itch imaginable). Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours.

    Time frame: Baseline, Week 12

  5. Change From Baseline in Dermatology-Specific Quality of Life Index (DLQI) Score

    DLQI is a participant-administered, 10-question, validated, quality-of-life questionnaire that covers 6 domains, including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include 0 (not at all), 1 (a little), 2 (a lot), and 3 (very much) and unanswered ("not relevant") responses were scored as "0." Total scores range from 0 to 30, with higher score indicating greater quality of life is impairment. A 5-point change from baseline is considered clinically relevant. Least squares (LS) mean change from baseline was calculated using mixed model repeated measures (MMRM).

    Time frame: Baseline, Week 12

  6. Change From Baseline in Nail Psoriasis Severity Index (NAPSI)

    The NAPSI is a numeric, reproducible, objective tool for evaluation of fingernail Ps. This scale is used to evaluate the severity of fingernail bed Ps and fingernail matrix Ps by area of involvement in the fingernail unit. The fingernail is divided with imaginary horizontal and longitudinal lines into quadrants. Each fingernail is given a score for fingernail bed Ps 0 (none) to 4 (Ps in 4 quadrants of the fingernail) and fingernail matrix Ps 0 (none) to 4 (Ps in 4 quadrants of the matrix), depending on the presence (score of 1) or absence (score of 0) of any of the features of fingernail bed or matrix Ps in each quadrant. The NAPSI score of a fingernail is the sum of scores in fingernail bed and fingernail matrix from each quadrant (maximum of 8). Each fingernail is evaluated, then the sum of all fingernails equals the total NAPSI score with a range from 0 to 80 with higher scores indicating more severe psoriasis. LS mean change from baseline was calculated using MMRM.

    Time frame: Baseline, Week 12

  7. Percent of Body Surface Area (BSA) Involvement of Ps

    BSA is a physician rating of the percentage of involvement of Ps for each participant. BSA is assessed on a continuous scale from 0% (no involvement) to 100% (full involvement), where 1% corresponds to the size of the participants hand (includes the palm, fingers and thumb). Total BSA is the sum of handprints from the affected areas. LS mean change from baseline was calculated using MMRM.

    Time frame: Week 12

  8. Change From Baseline in Psoriasis Scalp Severity Index (PSSI)

    The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (\<10%) to 6 (90%-100%) with a total scores range from 0 to 72, with lower scores indicating less severity. LS mean change from baseline was calculated using MMRM.

    Time frame: Baseline, Week 12

  9. Change From Baseline in All Scores of the Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO) Quality of Life and Outcome Assessments. Measures: Participant Reported Outcomes (PRO)

    WPAI-PSO is a participant administered, 6-item instrument used to assess the impact of Ps on the productivity impairment within the past 7 days. WPAI-PSO has 4 domains: absenteeism, presenteeism (reduced productivity while at work), an overall work impairment score, and impairment in daily activities performed outside of work. Four scores are derived as percentages: absenteeism, presenteeism (reduced productivity while at work), overall work impairment (absenteeism and presenteeism), and impairment in activities performed outside of work. Percentage is calculated as: each score \* 100 with greater scores indicating greater impairment. LS mean change from baseline was calculated using analysis of covariance (ANCOVA).

    Time frame: Baseline, Week 12

  10. Change From Baseline in Quick Inventory of Depressive Symptomatology-Self Reported 16 Items (QIDS-SR16)

    QIDS-SR16 is a participant-administered, 16-item instrument intended to assess the existence and severity of symptoms of depression. A participant is asked to consider each statement as it relates to the way they have felt for the past 7 days and rate each on a 4-point scale: 0 (best) to 3 (worst). The sum of the 16 items corresponding to 9 depression domains \[sad mood, concentration, self-criticism, suicidal ideation, interest, energy/fatigue, sleep disturbance (initial, middle and late insomnia or hypersomnia), decrease/increase in appetite/weight, and psychomotor agitation/retardation\] to give a single total scores range from 0 to 27, with higher scores indicating greater symptom severity. LS mean change from baseline was calculated using ANCOVA.

    Time frame: Baseline, Week 12

  11. Change From Baseline in Medical Outcomes Study 36-item Short Form Health Survey (SF-36) and Physical Component Summary (PCS) and Mental Component Summary (MCS)

    The SF-36 is a self-reported instrument that measures the participant's health status during the previous 7 days. It comprises 36-items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped in the PCS and MCS scores. Scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LS mean change from baseline was calculated using ANCOVA.

    Time frame: Baseline, Week 12

  12. Change From Baseline in Patient's Global Assessment of Disease Severity (PatGA)

    The PatGA is a single-item self-reported instrument asking the participant to rate the severity of their psoriasis "today" by circling a number on the numeric rating scale from 0 (Clear = no psoriasis) to 5 (Severe = the worst their psoriasis has ever been). LS mean change from baseline calculated using MMRM.

    Time frame: Baseline, Week 12

  13. Percentage of Participants Achieving Palmoplantar PASI (PPASI) of ≥50% (PPASI50), ≥75% (PPASI75), or 100% (PPASI100) Improvement

    The Palmoplantar PASI is a composite score derived from the sum of scores for erythema, induration, and desquamation \[scores range from 0 (none) to 4 (very severe) for each\] multiplied by the score for the extent of palm and sole area involvement \[scores range from 0 (0%) to 6 (90 to100%)\], with a total scores range from 0 to 72. Participants achieving PPASI50, PPASI75 or PASI100 were defined as having an improvement of at least 50%, 90%, or of 100%, respectively, in the PPASI scores compared to baseline.

    Time frame: Week 12

  14. Pharmacokinetics (PK): Trough Concentration at Steady State (Ctrough ss)

    Time frame: Weeks 12: Day 84 and Week 24: Day 168

  15. Percentage of Participants With Anti-ixekizumab Antibodies

    Percentage of participants with treatment-emergent positive anti-ixekizumab antibodies was summarized by treatment group. Percentage was calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants \* 100%.

    Time frame: Baseline through Week 12

07

Results

Posted May 27, 2016

Participant flow

Induction Period (Week 0 to 12), Maintenance Period (Week 12 to 60); Long term Extension (Week 60 to 264) and Post treatment ( last treatment visit (week 264), or Early Termination Visit (ETV) up to a minimum of 12 weeks following that visit.

Induction Period
Participant flow — Induction Period
MilestonePlacebo- Induction PeriodIxe Q4W - Induction PeriodIxe Q2W - Induction PeriodIxe/Placebo- Maintenance Period Primary PopIxe/Ixe Q12W - Maintenance Period Primary PopIxe/Ixe Q4W - Maintenance Period Primary PopPlacebo Resp/Placebo - Maintenance Period Secondary PopPlacebo Non-Resp/Ixe Q4W - Maintenance Period Secondary PopIxe Q4W Non-Resp/Ixe Q4W- Maintenance Period Secondary PopQ2W Non-Resp/Q4W - Maintenance Period Secondary PopIxe Q4W - Maintenance Period Relapsed PopulationPlacebo Long-Term Extension (LTE)Ixe Long-Term ExtensionTotal Ixe Long-Term ExtensionPlacebo Post-Treatment Follow-UpIxe Q12W Post-Treatment Follow-UpIxe Q4W Post-Treatment Follow-UpIxe Q2W Post-Treatment Follow-Up
Started431432433000000000000000
Received study drug431432433000000000000000
Completed407408415000000000000000
Not completed242418000000000000000
Withdrew: Adverse event61010000000000000000
Withdrew: Lack of efficacy710000000000000000
Withdrew: Withdrawal by subject665000000000000000
Withdrew: Protocol violation360000000000000000
Withdrew: Sponsor decision111000000000000000
Withdrew: Lost to follow-up102000000000000000
Maintenance Period
Participant flow — Maintenance Period
MilestonePlacebo- Induction PeriodIxe Q4W - Induction PeriodIxe Q2W - Induction PeriodIxe/Placebo- Maintenance Period Primary PopIxe/Ixe Q12W - Maintenance Period Primary PopIxe/Ixe Q4W - Maintenance Period Primary PopPlacebo Resp/Placebo - Maintenance Period Secondary PopPlacebo Non-Resp/Ixe Q4W - Maintenance Period Secondary PopIxe Q4W Non-Resp/Ixe Q4W- Maintenance Period Secondary PopQ2W Non-Resp/Q4W - Maintenance Period Secondary PopIxe Q4W - Maintenance Period Relapsed PopulationPlacebo Long-Term Extension (LTE)Ixe Long-Term ExtensionTotal Ixe Long-Term ExtensionPlacebo Post-Treatment Follow-UpIxe Q12W Post-Treatment Follow-UpIxe Q4W Post-Treatment Follow-UpIxe Q2W Post-Treatment Follow-Up
Started00022622722916391786200000000
Received study drug00022622722916391786200000000
Relapsed population received drug00000000003480000000
Relapsed population completers00000000003210000000
Completed000241081776350624400000000
Not completed000202119521041161800000000
Withdrew: Relapsed (spga ≥3)00018611139900000000000
Withdrew: Adverse event0004270191300000000
Withdrew: Withdrawal by subject000623163100000000
Withdrew: Lost to follow-up000330021100000000
Withdrew: Death000002000000000000
Withdrew: Physician decision000001020000000000
Withdrew: Clinical relapse000100000000000000
Withdrew: Lack of efficacy000100011111200000000
Withdrew: Protocol violation000100010100000000
Withdrew: Treated but discontinued in induction000010000000000000
Long-Term Extension Period
Participant flow — Long-Term Extension Period
MilestonePlacebo- Induction PeriodIxe Q4W - Induction PeriodIxe Q2W - Induction PeriodIxe/Placebo- Maintenance Period Primary PopIxe/Ixe Q12W - Maintenance Period Primary PopIxe/Ixe Q4W - Maintenance Period Primary PopPlacebo Resp/Placebo - Maintenance Period Secondary PopPlacebo Non-Resp/Ixe Q4W - Maintenance Period Secondary PopIxe Q4W Non-Resp/Ixe Q4W- Maintenance Period Secondary PopQ2W Non-Resp/Q4W - Maintenance Period Secondary PopIxe Q4W - Maintenance Period Relapsed PopulationPlacebo Long-Term Extension (LTE)Ixe Long-Term ExtensionTotal Ixe Long-Term ExtensionPlacebo Post-Treatment Follow-UpIxe Q12W Post-Treatment Follow-UpIxe Q4W Post-Treatment Follow-UpIxe Q2W Post-Treatment Follow-Up
Started0000000000026105410750000
Completed0000000000008368550000
Not completed00000000000262182200000
Withdrew: Withdrawal by subject00000000000361610000
Withdrew: Adverse event00000000000157580000
Withdrew: Lost to follow-up00000000000025250000
Withdrew: Lack of efficacy00000000000124250000
Withdrew: Physician decision00000000000021210000
Withdrew: Clinical relapse000000000000990000
Withdrew: Death000000000000990000
Withdrew: Sponsor decision000000000000660000
Withdrew: Protocol violation000000000000550000
Withdrew: Parent/caregiver decision000000000000110000
Withdrew: Switched from pbo to ixe0000000000021000000
Post-Treatment Follow-Up
Participant flow — Post-Treatment Follow-Up
MilestonePlacebo- Induction PeriodIxe Q4W - Induction PeriodIxe Q2W - Induction PeriodIxe/Placebo- Maintenance Period Primary PopIxe/Ixe Q12W - Maintenance Period Primary PopIxe/Ixe Q4W - Maintenance Period Primary PopPlacebo Resp/Placebo - Maintenance Period Secondary PopPlacebo Non-Resp/Ixe Q4W - Maintenance Period Secondary PopIxe Q4W Non-Resp/Ixe Q4W- Maintenance Period Secondary PopQ2W Non-Resp/Q4W - Maintenance Period Secondary PopIxe Q4W - Maintenance Period Relapsed PopulationPlacebo Long-Term Extension (LTE)Ixe Long-Term ExtensionTotal Ixe Long-Term ExtensionPlacebo Post-Treatment Follow-UpIxe Q12W Post-Treatment Follow-UpIxe Q4W Post-Treatment Follow-UpIxe Q2W Post-Treatment Follow-Up
Started000000000000001825700285
Completed00000000000000017544239
Not completed0000000000000018815646
Withdrew: Adverse event00000000000000825811
Withdrew: Withdrawal by subject00000000000000323617
Withdrew: Lack of efficacy0000000000000032313
Withdrew: Lost to follow-up0000000000000000127
Withdrew: Physician decision000000000000000045
Withdrew: Clinical relapse000000000000000062
Withdrew: Protocol violation000000000000002240
Withdrew: Sponsor decision000000000000001040
Withdrew: Parent/caregiver decision000000000000001001
Withdrew: Death000000000000000010

Outcome measures

PrimaryPercentage of Participants With Static Physician Global Assessment (sPGA) of 0 or 1 (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Ps Measure: sPGA)

The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of "0" or "1" with at least a 2-point improvement from baseline.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Static Physician Global Assessment (sPGA) of 0 or 1 (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Ps Measure: sPGA)
percentage of participantsPlaceboIxe Q4WIxe Q2W
Percentage of Participants With Static Physician Global Assessment (sPGA) of 0 or 1 (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Ps Measure: sPGA)3.276.481.8
Statistical analysis
  • Placebo vs Ixe Q4W · Regression, Logistic · p = <0.001Logistic Regression analysis included treatment, geographic region, previous non-biologic systemic therapy and baseline weight category as factors.
  • Placebo vs Ixe Q2W · Regression, Logistic · p = <0.001Logistic Regression analysis included treatment, geographic region, previous non-biologic systemic therapy and baseline weight category as factors.
PrimaryPercentage of Participants Achieving ≥75% Improvement in Ps Area and Severity Index (PASI75) (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Psoriasis Measure: PASI)

The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease). Participants achieving PASI75 were defined as having an improvement of ≥75% in the PASI score compared to baseline.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ≥75% Improvement in Ps Area and Severity Index (PASI75) (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Psoriasis Measure: PASI)
percentage of participantsPlaceboIxe Q4WIxe Q2W
Percentage of Participants Achieving ≥75% Improvement in Ps Area and Severity Index (PASI75) (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Psoriasis Measure: PASI)3.982.689.1
Statistical analysis
  • Placebo vs Ixe Q4W · Regression, Logistic · p = <0.001Logistic Regression analysis included treatment, geographic region, previous non-biologic systemic therapy and baseline weight category as factors.
  • Placebo vs Ixe Q2W · Regression, Logistic · p = <0.001Logistic Regression analysis included treatment, geographic region, previous non-biologic systemic therapy and baseline weight category as factors.
SecondaryPercentage of Participants Achieving an sPGA of 0 (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Ps Measure: sPGA)

The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe).

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving an sPGA of 0 (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Ps Measure: sPGA)
percentage of participantsPlaceboIxe Q4WIxe Q2W
Percentage of Participants Achieving an sPGA of 0 (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Ps Measure: sPGA)0.034.537.0
Statistical analysis
  • Placebo vs Ixe Q4W · Fisher Exact · p = <0.001Due to the zero count in placebo group, p-values from Logistic Regression were not obtainable, therefore the p-value is from Fisher's exact test.
  • Placebo vs Ixe Q2W · Fisher Exact · p = <0.001Due to the zero count in placebo group, p-values from Logistic Regression were not obtainable, therefore the p-value is from Fisher's exact test.
SecondaryPercentage of Participants Achieving PASI 90% (PASI90) or 100% (PASI100) (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Ps Measure: PASI)

The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease). Participants achieving PASI90 or PASI100 were defined as having an improvement of ≥90% or of 100% respectively in PASI scores compared to baseline.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving PASI 90% (PASI90) or 100% (PASI100) (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Ps Measure: PASI)
percentage of participantsPlaceboIxe Q4WIxe Q2W
PASI900.564.670.9
PASI1000.033.635.3
Statistical analysis
  • Placebo vs Ixe Q4W · Regression, Logistic · p = <0.001 (P-value is for PASI90.)Logistic Regression analysis included treatment, geographic region, previous non-biologic systemic therapy and baseline weight category as factors.
  • Placebo vs Ixe Q2W · Regression, Logistic · p = <0.001 (P-value is for PASI90.)Logistic Regression analysis included treatment, geographic region, previous non-biologic systemic therapy and baseline weight category as factors.
  • Placebo vs Ixe Q4W · Fisher Exact · p = <0.001 (P-value is for PASI100.)Due to the zero count in placebo group, p-values from Logistic Regression were not obtainable; therefore the p-value is from Fisher's exact test.
  • Placebo vs Ixe Q2W · Fisher Exact · p = <0.001 (P-value is for PASI100.)Due to the zero count in placebo group, p-values from Logistic Regression were not obtainable; therefore the p-value is from Fisher's exact test.
SecondaryPercentage of Participants Maintaining sPGA 0 or 1 After Re-Randomization at Start of Maintenance Dosing Period

The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe).

Time frame:
Week 60
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining sPGA 0 or 1 After Re-Randomization at Start of Maintenance Dosing Period
percentage of participantsIxe/PlaceboIxe/Q12WIxe/Q4W
Percentage of Participants Maintaining sPGA 0 or 1 After Re-Randomization at Start of Maintenance Dosing Period7.537.472.9
Statistical analysis
  • Ixe/Placebo vs Ixe/Q12W · Regression, Logistic · p = <0.001Logistic Regression analysis included treatment and baseline weight category as factors.
  • Ixe/Placebo vs Ixe/Q4W · Regression, Logistic · p = <0.001Logistic Regression analysis included treatment and baseline weight category as factors.
SecondaryPercentage of Participants With Itch Numeric Rating Scale (Itch NRS) Score ≥4 Point Reduction From Baseline

The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 (no itch) and 10 (worst itch imaginable). Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours.

Time frame:
Baseline, Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Itch Numeric Rating Scale (Itch NRS) Score ≥4 Point Reduction From Baseline
percentage of participantsPlaceboIxe Q4WIxe Q2W
Percentage of Participants With Itch Numeric Rating Scale (Itch NRS) Score ≥4 Point Reduction From Baseline15.580.585.9
Statistical analysis
  • Placebo vs Ixe Q4W · Regression, Logistic · p = <0.001Logistic Regression analysis included treatment, geographic region, previous non-biologic systemic therapy and baseline weight category as factors.
  • Placebo vs Ixe Q2W · Regression, Logistic · p = <0.001Logistic Regression analysis included treatment, geographic region, previous non-biologic systemic therapy and baseline weight category as factors.
SecondaryChange From Baseline in Dermatology-Specific Quality of Life Index (DLQI) Score

DLQI is a participant-administered, 10-question, validated, quality-of-life questionnaire that covers 6 domains, including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include 0 (not at all), 1 (a little), 2 (a lot), and 3 (very much) and unanswered ("not relevant") responses were scored as "0." Total scores range from 0 to 30, with higher score indicating greater quality of life is impairment. A 5-point change from baseline is considered clinically relevant. Least squares (LS) mean change from baseline was calculated using mixed model repeated measures (MMRM).

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Dermatology-Specific Quality of Life Index (DLQI) Score
units on a scalePlaceboIxe Q4WIxe Q2W
Change From Baseline in Dermatology-Specific Quality of Life Index (DLQI) Score-1.0 ± 0.27-10.7 ± 0.27-11.1 ± 0.26
Statistical analysis
  • Placebo vs Ixe Q4W · Mixed Models Analysis · p = <0.001 (LS mean and P-value were calculated using MMRM with baseline score as a covariate, treatment, geographic region, previous non-biologic systemic therapy, baseline weight category, visit and treatment-by-visit interaction as fixed effects.)
  • Placebo vs Ixe Q2W · Mixed Models Analysis · p = <0.001 (LS mean and P-value were calculated using MMRM with baseline score as a covariate, treatment, geographic region, previous non-biologic systemic therapy, baseline weight category, visit and treatment-by-visit interaction as fixed effects.)
SecondaryChange From Baseline in Nail Psoriasis Severity Index (NAPSI)

The NAPSI is a numeric, reproducible, objective tool for evaluation of fingernail Ps. This scale is used to evaluate the severity of fingernail bed Ps and fingernail matrix Ps by area of involvement in the fingernail unit. The fingernail is divided with imaginary horizontal and longitudinal lines into quadrants. Each fingernail is given a score for fingernail bed Ps 0 (none) to 4 (Ps in 4 quadrants of the fingernail) and fingernail matrix Ps 0 (none) to 4 (Ps in 4 quadrants of the matrix), depending on the presence (score of 1) or absence (score of 0) of any of the features of fingernail bed or matrix Ps in each quadrant. The NAPSI score of a fingernail is the sum of scores in fingernail bed and fingernail matrix from each quadrant (maximum of 8). Each fingernail is evaluated, then the sum of all fingernails equals the total NAPSI score with a range from 0 to 80 with higher scores indicating more severe psoriasis. LS mean change from baseline was calculated using MMRM.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Nail Psoriasis Severity Index (NAPSI)
units on a scalePlaceboIxe Q4WIxe Q2W
Change From Baseline in Nail Psoriasis Severity Index (NAPSI)2.17 ± 0.672-7.19 ± 0.671-7.24 ± 0.657
Statistical analysis
  • Placebo vs Ixe Q4W · Mixed Models Analysis · p = <0.001 (LS mean and P-value were calculated using MMRM with baseline score as a covariate, treatment, geographic region, previous non-biologic systemic therapy, baseline weight category, visit and treatment-by-visit interaction as fixed effects.)
  • Placebo vs Ixe Q2W · Mixed Models Analysis · p = <0.001 (LS mean and P-value were calculated using MMRM with baseline score as a covariate, treatment, geographic region, previous non-biologic systemic therapy, baseline weight category, visit and treatment-by-visit interaction as fixed effects.)
SecondaryPercent of Body Surface Area (BSA) Involvement of Ps

BSA is a physician rating of the percentage of involvement of Ps for each participant. BSA is assessed on a continuous scale from 0% (no involvement) to 100% (full involvement), where 1% corresponds to the size of the participants hand (includes the palm, fingers and thumb). Total BSA is the sum of handprints from the affected areas. LS mean change from baseline was calculated using MMRM.

Time frame:
Week 12
Reported as:
Least squares mean · percentage of body surface
Percent of Body Surface Area (BSA) Involvement of Ps
percentage of body surfacePlaceboIxe Q4WIxe Q2W
Percent of Body Surface Area (BSA) Involvement of Ps1.3 ± 0.67-21.4 ± 0.67-22.4 ± 0.66
Statistical analysis
  • Placebo vs Ixe Q4W · Mixed Models Analysis · p = <0.001 (LS mean and P-value were calculated using MMRM with baseline score as a covariate, treatment, geographic region, previous non-biologic systemic therapy, baseline weight category, visit and treatment-by-visit interaction as fixed effects.)
  • Placebo vs Ixe Q2W · Mixed Models Analysis · p = <0.001 (LS mean and P-value were calculated using MMRM with baseline score as a covariate, treatment, geographic region, previous non-biologic systemic therapy, baseline weight category, visit and treatment-by-visit interaction as fixed effects.)
SecondaryChange From Baseline in Psoriasis Scalp Severity Index (PSSI)

The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (\<10%) to 6 (90%-100%) with a total scores range from 0 to 72, with lower scores indicating less severity. LS mean change from baseline was calculated using MMRM.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Psoriasis Scalp Severity Index (PSSI)
units on a scalePlaceboIxe Q4WIxe Q2W
Change From Baseline in Psoriasis Scalp Severity Index (PSSI)-1.8 ± 0.53-18.3 ± 0.52-19.2 ± 0.52
Statistical analysis
  • Placebo vs Ixe Q4W · Mixed Models Analysis · p = <0.001 (LS mean and P-value were calculated using MMRM with baseline score as a covariate, treatment, geographic region, previous non-biologic systemic therapy, baseline weight category, visit and treatment-by-visit interaction as fixed effects.)
  • Placebo vs Ixe Q2W · Mixed Models Analysis · p = <0.001 (LS mean and P-value were calculated using MMRM with baseline score as a covariate, treatment, geographic region, previous non-biologic systemic therapy, baseline weight category, visit and treatment-by-visit interaction as fixed effects.)
SecondaryChange From Baseline in All Scores of the Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO) Quality of Life and Outcome Assessments. Measures: Participant Reported Outcomes (PRO)

WPAI-PSO is a participant administered, 6-item instrument used to assess the impact of Ps on the productivity impairment within the past 7 days. WPAI-PSO has 4 domains: absenteeism, presenteeism (reduced productivity while at work), an overall work impairment score, and impairment in daily activities performed outside of work. Four scores are derived as percentages: absenteeism, presenteeism (reduced productivity while at work), overall work impairment (absenteeism and presenteeism), and impairment in activities performed outside of work. Percentage is calculated as: each score \* 100 with greater scores indicating greater impairment. LS mean change from baseline was calculated using analysis of covariance (ANCOVA).

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in All Scores of the Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO) Quality of Life and Outcome Assessments. Measures: Participant Reported Outcomes (PRO)
units on a scalePlaceboIxe Q4WIxe Q2W
Absenteeism0.2 ± 0.88-3.5 ± 0.87-2.6 ± 0.84
Activity Impairment0.8 ± 1.18-24.5 ± 1.18-25.2 ± 1.15
Presenteeism0.5 ± 1.30-18.8 ± 1.28-18.3 ± 1.24
Work Productivity Loss-0.8 ± 1.40-20.6 ± 1.38-19.8 ± 1.33
Statistical analysis
  • Placebo vs Ixe Q4W · ANCOVA · p = <0.001 (The LS Mean and p-values were calculated using an ANCOVA model and included treatment, geographic region, previous non-biologic systemic therapy, baseline weight category, and baseline WPAI value.)P-value is for Absenteeism.
  • Placebo vs Ixe Q2W · ANCOVA · p = 0.003 (The LS Mean and p-values were calculated using an ANCOVA model and included treatment, geographic region, previous non-biologic systemic therapy, baseline weight category, and baseline WPAI value.)P-value is for absenteeism.
  • Placebo vs Ixe Q4W · ANCOVA · p = <0.001 (The LS Mean and p-values were calculated using an ANCOVA model and included treatment, geographic region, previous non-biologic systemic therapy, baseline weight category, and baseline WPAI value.)P-value is for activity impairment.
  • Placebo vs Ixe Q2W · ANCOVA · p = <0.001 (The LS Mean and p-values were calculated using an ANCOVA model and included treatment, geographic region, previous non-biologic systemic therapy, baseline weight category, and baseline WPAI value.)P-value is for activity impairment.
  • Placebo vs Ixe Q4W · ANCOVA · p = <0.001 (The LS Mean and p-values were calculated using an ANCOVA model and included treatment, geographic region, previous non-biologic systemic therapy, baseline weight category, and baseline WPAI value.)P-value is for presenteeism.
  • Placebo vs Ixe Q2W · ANCOVA · p = <0.001 (The LS Mean and p-values were calculated using an ANCOVA model and included treatment, geographic region, previous non-biologic systemic therapy, baseline weight category, and baseline WPAI value.)P-value is for presenteeism.
  • Placebo vs Ixe Q4W · ANCOVA · p = <0.001 (The LS Mean and p-values were calculated using an ANCOVA model and included treatment, geographic region, previous non-biologic systemic therapy, baseline weight category, and baseline WPAI value.)P-value is for work productively loss.
  • Placebo vs Ixe Q2W · ANCOVA · p = <0.001 (The LS Mean and p-values were calculated using an ANCOVA model and included treatment, geographic region, previous non-biologic systemic therapy, baseline weight category, and baseline WPAI value.)P-value is for work productively loss.
SecondaryChange From Baseline in Quick Inventory of Depressive Symptomatology-Self Reported 16 Items (QIDS-SR16)

QIDS-SR16 is a participant-administered, 16-item instrument intended to assess the existence and severity of symptoms of depression. A participant is asked to consider each statement as it relates to the way they have felt for the past 7 days and rate each on a 4-point scale: 0 (best) to 3 (worst). The sum of the 16 items corresponding to 9 depression domains \[sad mood, concentration, self-criticism, suicidal ideation, interest, energy/fatigue, sleep disturbance (initial, middle and late insomnia or hypersomnia), decrease/increase in appetite/weight, and psychomotor agitation/retardation\] to give a single total scores range from 0 to 27, with higher scores indicating greater symptom severity. LS mean change from baseline was calculated using ANCOVA.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Quick Inventory of Depressive Symptomatology-Self Reported 16 Items (QIDS-SR16)
units on a scalePlaceboIxe Q4WIxe Q2W
Change From Baseline in Quick Inventory of Depressive Symptomatology-Self Reported 16 Items (QIDS-SR16)-0.1 ± 0.17-1.0 ± 0.17-1.3 ± 0.17
Statistical analysis
  • Placebo vs Ixe Q4W · ANCOVA · p = <0.001 (LS Mean and p-values were calculated using an ANCOVA model that included treatment, geographic region, previous non-biologic systemic therapy, baseline weight category, and baseline QIDS value in the model.)
  • Placebo vs Ixe Q2W · ANCOVA · p = <0.001 (LS Mean and p-values were calculated using an ANCOVA model that included treatment, geographic region, previous non-biologic systemic therapy, baseline weight category, and baseline QIDS value in the model.)
SecondaryChange From Baseline in Medical Outcomes Study 36-item Short Form Health Survey (SF-36) and Physical Component Summary (PCS) and Mental Component Summary (MCS)

The SF-36 is a self-reported instrument that measures the participant's health status during the previous 7 days. It comprises 36-items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped in the PCS and MCS scores. Scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LS mean change from baseline was calculated using ANCOVA.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Medical Outcomes Study 36-item Short Form Health Survey (SF-36) and Physical Component Summary (PCS) and Mental Component Summary (MCS)
units on a scalePlaceboIxe Q4WIxe Q2W
PCS-0.1747 ± 0.40124.3081 ± 0.39904.3159 ± 0.3878
MCS0.8729 ± 0.46383.7386 ± 0.46334.1293 ± 0.4480
Statistical analysis
  • Placebo vs Ixe Q4W · ANCOVA · p = <0.001 (The LS Mean and p-values were calculated using an ANCOVA model and included treatment, geographic region, previous non-biologic systemic therapy, baseline weight category, and baseline SF-36 value in the model.)P-value is for PCS.
  • Placebo vs Ixe Q2W · ANCOVA · p = <0.001 (The LS Mean and p-values were calculated using an ANCOVA model and included treatment, geographic region, previous non-biologic systemic therapy, baseline weight category, and baseline SF-36 value in the model.)P-value is for PCS.
  • Placebo vs Ixe Q4W · ANCOVA · p = <0.001 (The LS Mean and p-values were calculated using an ANCOVA model and included treatment, geographic region, previous non-biologic systemic therapy, baseline weight category, and baseline SF-36 value in the model.)P-value is for MCS.
  • Placebo vs Ixe Q2W · ANCOVA · p = <0.001 (The LS Mean and p-values were calculated using an ANCOVA model and included treatment, geographic region, previous non-biologic systemic therapy, baseline weight category, and baseline SF-36 value in the model.)P-value is for MCS.
SecondaryChange From Baseline in Patient's Global Assessment of Disease Severity (PatGA)

The PatGA is a single-item self-reported instrument asking the participant to rate the severity of their psoriasis "today" by circling a number on the numeric rating scale from 0 (Clear = no psoriasis) to 5 (Severe = the worst their psoriasis has ever been). LS mean change from baseline calculated using MMRM.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Patient's Global Assessment of Disease Severity (PatGA)
units on a scalePlaceboIxe Q4WIxe Q2W
Change From Baseline in Patient's Global Assessment of Disease Severity (PatGA)-0.2 ± 0.06-3.1 ± 0.06-3.2 ± 0.06
Statistical analysis
  • Placebo vs Ixe Q4W · Mixed Models Analysis · p = <0.001 (LS mean and P-value were calculated using MMRM with baseline score as a covariate, treatment, geographic region, previous non-biologic systemic therapy, baseline weight category, visit and treatment-by-visit interaction as fixed effects.)
  • Placebo vs Ixe Q2W · Mixed Models Analysis · p = <0.001 (LS mean and P-value were calculated using MMRM with baseline score as a covariate, treatment, geographic region, previous non-biologic systemic therapy, baseline weight category, visit and treatment-by-visit interaction as fixed effects.)
SecondaryPercentage of Participants Achieving Palmoplantar PASI (PPASI) of ≥50% (PPASI50), ≥75% (PPASI75), or 100% (PPASI100) Improvement

The Palmoplantar PASI is a composite score derived from the sum of scores for erythema, induration, and desquamation \[scores range from 0 (none) to 4 (very severe) for each\] multiplied by the score for the extent of palm and sole area involvement \[scores range from 0 (0%) to 6 (90 to100%)\], with a total scores range from 0 to 72. Participants achieving PPASI50, PPASI75 or PASI100 were defined as having an improvement of at least 50%, 90%, or of 100%, respectively, in the PPASI scores compared to baseline.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Palmoplantar PASI (PPASI) of ≥50% (PPASI50), ≥75% (PPASI75), or 100% (PPASI100) Improvement
percentage of participantsPlaceboIxe Q4WIxe Q2W
PPASI5035.384.082.9
PPASI7526.374.877.1
PPASI10020.365.670.0
Statistical analysis
  • Placebo vs Ixe Q4W · Regression, Logistic · p = <0.001 (P-value is for PPASI50.)Logistic Regression analysis included treatment, geographic region, previous non-biologic systemic therapy and baseline weight category as factors.
  • Placebo vs Ixe Q2W · Regression, Logistic · p = <0.001 (P-value is for PPASI50.)Logistic Regression analysis included treatment, geographic region, previous non-biologic systemic therapy and baseline weight category as factors.
  • Placebo vs Ixe Q4W · Regression, Logistic · p = <0.001 (P-value is for PPASI75)Logistic Regression analysis included treatment, geographic region, previous non-biologic systemic therapy and baseline weight category as factors.
  • Placebo vs Ixe Q2W · Regression, Logistic · p = <0.001 (P-value is for PPASI75)Logistic Regression analysis included treatment, geographic region, previous non-biologic systemic therapy and baseline weight category as factors.
  • Placebo vs Ixe Q4W · Regression, Logistic · p = <0.001 (P-value is for PPASI100)Logistic Regression analysis included treatment, geographic region, previous non-biologic systemic therapy and baseline weight category as factors.
  • Placebo vs Ixe Q2W · Regression, Logistic · p = <0.001 (P-value if for PPASI100.)Logistic Regression analysis included treatment, geographic region, previous non-biologic systemic therapy and baseline weight category as factors.
SecondaryPharmacokinetics (PK): Trough Concentration at Steady State (Ctrough ss)
Time frame:
Weeks 12: Day 84 and Week 24: Day 168
Reported as:
Geometric mean · micrograms/milliliter (µg/mL)
Pharmacokinetics (PK): Trough Concentration at Steady State (Ctrough ss)
micrograms/milliliter (µg/mL)Ixe Q2W - Induction PeriodIxe Q4W - Induction PeriodIxe Q4W - Maintenance PeriodIxe Q12W - Maintenance Period
Week 127.73 ± 792.94 ± 89NA ± NANA ± NA
Week 24NA ± NANA ± NA2.36 ± 1110.281 ± 175
SecondaryPercentage of Participants With Anti-ixekizumab Antibodies

Percentage of participants with treatment-emergent positive anti-ixekizumab antibodies was summarized by treatment group. Percentage was calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants \* 100%.

Time frame:
Baseline through Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Anti-ixekizumab Antibodies
percentage of participantsPlaceboIxe Q4WIxe Q2W
Percentage of Participants With Anti-ixekizumab Antibodies0.512.510.3

Adverse events

Collected over Up to 276 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo - Induction Period—5/431 (1.2%)128/431 (29.7%)
Ixe Q4W - Induction Period—12/432 (2.8%)159/432 (36.8%)
Ixe Q2W - Induction Period—7/433 (1.6%)170/433 (39.3%)
Ixe/Placebo- Maintenance Period Primary Pop—7/226 (3.1%)83/226 (36.7%)
Ixe/Ixe Q12W - Maintenance Period Primary Pop—11/227 (4.8%)122/227 (53.7%)
Ixe/Ixe Q4W - Maintenance Period Primary Pop—14/229 (6.1%)115/229 (50.2%)
Placebo Resp/Placebo - Maintenance Period Secondary Pop—0/16 (0%)8/16 (50%)
Placebo Non-Resp/Ixe Q4W - Maintenance Period Secondary Pop—24/391 (6.1%)211/391 (54%)
Ixe Q4W Non-Resp/Ixe Q4W - Maintenance Period Secondary Pop—8/78 (10.3%)55/78 (70.5%)
Q2W Non-Resp/Q4W - Maintenance Period Secondary Pop—3/62 (4.8%)34/62 (54.8%)
Ixe Q4W - Maintenance Period Relapse Pop—11/348 (3.2%)114/348 (32.8%)
Placebo Long-Term Extension—1/26 (3.8%)8/26 (30.8%)
Ixe Long-Term Extension—134/1,054 (12.7%)414/1,054 (39.3%)
Total Ixe Long-Term Extension—134/1,075 (12.5%)414/1,075 (38.5%)
Placebo Post-Treatment Follow-Up—2/18 (11.1%)3/18 (16.7%)
Ixe Q12W Post-Treatment Follow-Up—0/25 (0%)2/25 (8%)
Ixe Q4W Post Treatment Follow-Up—13/700 (1.9%)33/700 (4.7%)
Ixe Q2W Post-Treatment Follow-Up—6/285 (2.1%)15/285 (5.3%)
Most frequent serious events
Showing 10 of 235
Most frequent serious events
EventPlacebo - Induction PeriodIxe Q4W - Induction PeriodIxe Q2W - Induction PeriodIxe/Placebo- Maintenance Period Primary PopIxe/Ixe Q12W - Maintenance Period Primary PopIxe/Ixe Q4W - Maintenance Period Primary PopPlacebo Resp/Placebo - Maintenance Period Secondary PopPlacebo Non-Resp/Ixe Q4W - Maintenance Period Secondary PopIxe Q4W Non-Resp/Ixe Q4W - Maintenance Period Secondary PopQ2W Non-Resp/Q4W - Maintenance Period Secondary PopIxe Q4W - Maintenance Period Relapse PopPlacebo Long-Term ExtensionIxe Long-Term ExtensionTotal Ixe Long-Term ExtensionPlacebo Post-Treatment Follow-UpIxe Q12W Post-Treatment Follow-UpIxe Q4W Post Treatment Follow-UpIxe Q2W Post-Treatment Follow-Up
EndometritisInfections and infestations0/1280/1430/1420/720/770/730/60/1150/240/210/1070/110/3230/3321/50/150/2150/78
Lacunar infarctionNervous system disorders0/4310/4320/4330/2260/2270/2290/160/3910/780/620/3480/260/10540/10751/180/250/7000/285
FallInjury, poisoning and procedural complications0/4310/4320/4331/2260/2271/2290/161/3910/780/621/3481/262/10542/10750/180/250/7000/285
Fibula fractureInjury, poisoning and procedural complications0/4310/4320/4330/2260/2270/2290/160/3910/780/620/3481/260/10540/10750/180/250/7000/285
Arteriospasm coronaryCardiac disorders0/4310/4320/4330/2260/2270/2290/160/3910/781/620/3480/260/10540/10750/180/250/7000/285
TinnitusEar and labyrinth disorders0/4310/4320/4330/2260/2270/2290/160/3910/781/620/3480/260/10540/10750/180/250/7000/285
Gastric ulcerGastrointestinal disorders0/4310/4320/4330/2260/2270/2290/160/3910/781/620/3480/260/10540/10750/180/250/7000/285
Mitral valve incompetenceCardiac disorders0/4310/4320/4330/2260/2270/2290/160/3911/780/620/3480/260/10540/10750/180/250/7000/285
Congenital pyelocaliectasisCongenital, familial and genetic disorders0/4310/4320/4330/2260/2270/2290/160/3911/780/620/3480/260/10540/10750/180/250/7000/285
Abdominal pain upperGastrointestinal disorders0/4310/4320/4330/2260/2270/2290/160/3911/780/620/3480/261/10541/10750/180/250/7000/285
Most frequent other events
Showing 10 of 31
Most frequent other events
EventPlacebo - Induction PeriodIxe Q4W - Induction PeriodIxe Q2W - Induction PeriodIxe/Placebo- Maintenance Period Primary PopIxe/Ixe Q12W - Maintenance Period Primary PopIxe/Ixe Q4W - Maintenance Period Primary PopPlacebo Resp/Placebo - Maintenance Period Secondary PopPlacebo Non-Resp/Ixe Q4W - Maintenance Period Secondary PopIxe Q4W Non-Resp/Ixe Q4W - Maintenance Period Secondary PopQ2W Non-Resp/Q4W - Maintenance Period Secondary PopIxe Q4W - Maintenance Period Relapse PopPlacebo Long-Term ExtensionIxe Long-Term ExtensionTotal Ixe Long-Term ExtensionPlacebo Post-Treatment Follow-UpIxe Q12W Post-Treatment Follow-UpIxe Q4W Post Treatment Follow-UpIxe Q2W Post-Treatment Follow-Up
NasopharyngitisInfections and infestations41/43145/43249/43326/22641/22751/2290/1677/39119/7811/6237/3484/26178/1054178/10750/180/259/7001/285
Upper respiratory tract infectionInfections and infestations16/43120/43224/43318/22620/22718/2292/1653/3918/784/6218/3482/2689/105489/10750/180/251/7000/285
ArthralgiaMusculoskeletal and connective tissue disorders9/4314/4329/4336/22613/22713/2290/1614/3918/783/624/3481/2654/105454/10750/180/253/7001/285
Injection site reactionGeneral disorders5/43127/43242/4332/2267/22712/2290/1636/3917/782/6213/3480/2627/105427/10750/180/250/7000/285
Back painMusculoskeletal and connective tissue disorders4/4316/4324/4337/22613/2276/2290/1616/3911/786/626/3480/2645/105445/10751/180/251/7000/285
PsoriasisSkin and subcutaneous tissue disorders16/4312/4324/4335/2266/2272/2291/164/3912/781/624/3480/2621/105421/10750/182/2511/7005/285
InfluenzaInfections and infestations0/4314/4322/4334/2268/2277/2290/167/3912/782/623/3482/2628/105428/10750/180/253/7002/285
HeadacheNervous system disorders15/43116/43218/4335/22616/2278/2290/1620/3916/782/626/3480/2630/105430/10750/180/251/7000/285
Injection site erythemaGeneral disorders0/43118/43228/4330/2263/2275/2290/1613/3913/780/622/3480/263/10543/10750/180/250/7000/285
CellulitisInfections and infestations0/4311/4320/4330/2261/2272/2290/164/3915/780/623/3480/2614/105414/10750/180/250/7001/285

Baseline characteristics

All randomized participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)PlaceboIxe Q4WIxe Q2WTotal
Mean46.4 ± 13.4045.6 ± 12.9545.1 ± 12.4045.7 ± 12.93
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboIxe Q4WIxe Q2WTotal
Female128143142413
Male303289291883
Region of Enrollment
Region of Enrollment(Participants)PlaceboIxe Q4WIxe Q2WTotal
Canada776966212
Romania83213
Hungary23172666
United States146156159461
Japan1312833
Denmark44816
Poland434155139
Italy3216
United Kingdom77721
Australia1915842
Germany8810693287
Static Physician Global Assessment (sPGA)
Static Physician Global Assessment (sPGA)(Participants)PlaceboIxe Q4WIxe Q2WTotal
sPGA=3204197231632
sPGA=4, 5227235202664
Psoriasis Area and Severity Index (PASI)
Psoriasis Area and Severity Index (PASI)(units on a scale)PlaceboIxe Q4WIxe Q2WTotal
Mean20.32 ± 8.64120.03 ± 7.30420.09 ± 7.99220.15 ± 7.992
Itch Numeric Rating Scale (NRS)
Itch Numeric Rating Scale (NRS)(units on a scale)PlaceboIxe Q4WIxe Q2WTotal
Mean7.0 ± 2.587.0 ± 2.507.2 ± 2.397.1 ± 2.49
Dermatology-Specific Quality of Life Index (DLQI) Score
Dermatology-Specific Quality of Life Index (DLQI) Score(units on a scale)PlaceboIxe Q4WIxe Q2WTotal
Mean12.8 ± 7.1113.2 ± 7.0213.4 ± 7.0213.1 ± 7.05
Nail Psoriasis Severity Index (NAPSI)
Nail Psoriasis Severity Index (NAPSI)(units on a scale)PlaceboIxe Q4WIxe Q2WTotal
Mean26.9 ± 20.49224.12 ± 18.24324.64 ± 18.91624.95 ± 19.238

6 further baseline measures are reported on the registry.

08

Study locations

104 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Birmingham, Alabama 35233, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Anaheim, California 92801, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bakersfield, California 93309, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fremont, California 94538, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    New Haven, Connecticut 06511, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Jacksonville, Florida 32216, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Miami, Florida 33175, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Miramar, Florida 33027, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ocala, Florida 34471, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ormond Beach, Florida 32174, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pinellas Park, Florida 33781, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tampa, Florida 33624, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    West Palm Beach, Florida 33409, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Atlanta, Georgia 30327, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Arlington Heights, Illinois 60005, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chicago, Illinois 60611, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Evansville, Indiana 47714, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Indianapolis, Indiana 46256, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    South Bend, Indiana 46617, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Owensboro, Kentucky 42303, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Baton Rouge, Louisiana 70809, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Troy, Michigan 48084, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Saint Louis, Missouri 63117, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bronx, New York 10467, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    New York, New York 10021, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rochester, New York 14623, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Raleigh, North Carolina 27612, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cleveland, Ohio 44106, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Portland, Oregon 97223, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Johnston, Rhode Island 02919, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Knoxville, Tennessee 37922, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Salt Lake City, Utah 84132, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bellingham, Washington 98225, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seattle, Washington 98101, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kogarah, New South Wales 2217, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Benowa, Queensland 4217, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Woolloogabba, Queensland 4120, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Adelaide, South Australia 5000, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Carlton, Victoria 3053, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Parkville, Victoria 3050, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fremantle, Western Australia 6160, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Surrey, British Columbia V3R 6A7, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Winnipeg, Manitoba R3C 1R4, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Moncton, New Brunswick E1C8X3, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Halifax, Nova Scotia B5H1Z4, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ajax, Ontario L1S7K8, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Barrie, Ontario L4M6L2, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    London, Ontario N6A 3H7, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Newmarket, Ontario L3Y6P5, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Richmond Hill, Ontario L4B 1A5, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Waterloo, Ontario N2J 1C4, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Windsor, Ontario N8W 1E6, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Montreal, Quebec H3Z 2S6, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Aarhus, 8000, Denmark
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hellerup, 2900, Denmark
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kobenhavn, 2400, Denmark
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Berlin, 13125, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Darmstadt, 64283, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Frankfurt, 60596, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hamburg, 22143, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hanau, 63450, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hannover, 30449, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kiel, 24105, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Köln, 50937, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mahlow, 39110, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mainz, 55131, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Münster, 48149, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Quedlinburg, 06484, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wuppertal, 42275, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Budapest, 1036, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Debrecen, 4032, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Miskolc, 3529, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Szeged, H-6720, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Szolnok, H-5000, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Szombathely, H-9700, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bergamo, 24128, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bologna, 40100, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Padova, 35128, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pisa, 56126, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Aichi, 467-0001, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fukuoka, 814-0180, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kochi, 783-8505, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kyoto, 602-0841, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Shiga, 520-2192, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Shizuoka, 431-3125, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tochigi, 329- 0498, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tokyo, 169-0073, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bialystok, 15-017, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Elblag, 82-300, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Krakow, 30-510, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lodz, 90-265, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lublin, 20-081, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Szczecin, 70-111, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Torun, 87-100, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Warsaw, 04-749, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Baia Mare, 430193, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bucharest, 21155, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Craiova, 200642, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Iasi, 700125, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Salford, Manchester M6 8HD, United Kingdom

Showing the first 100 of 104 sites across 11 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Elewski BE, Blauvelt A, Gallo G, Wolf E, McKean-Matthews M, Burge R, Merola JF, Gottlieb AB, Guenther LC. Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis. Dermatol Ther (Heidelb). 2022 Apr;12(4):911-920. doi: 10.1007/s13555-022-00704-2. Epub 2022 Mar 13. PubMed 35279805 ↗
  • Leonardi C, Reich K, Foley P, Torii H, Gerdes S, Guenther L, Gooderham M, Ferris LK, Griffiths CEM, ElMaraghy H, Crane H, Patel H, Burge R, Gallo G, Shrom D, Leung A, Lin CY, Papp K. Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials. Dermatol Ther (Heidelb). 2020 Jun;10(3):431-447. doi: 10.1007/s13555-020-00367-x. Epub 2020 Mar 21. PubMed 32200512 ↗
  • Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK, Cameron GS, Erickson J, Konrad RJ, Muram TM, Nickoloff BJ, Osuntokun OO, Secrest RJ, Zhao F, Mallbris L, Leonardi CL; UNCOVER-1 Study Group; UNCOVER-2 Study Group; UNCOVER-3 Study Group. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. N Engl J Med. 2016 Jul 28;375(4):345-56. doi: 10.1056/NEJMoa1512711. Epub 2016 Jun 8. PubMed 27299809 ↗
  • Armstrong AW, Lynde CW, McBride SR, Stahle M, Edson-Heredia E, Zhu B, Amato D, Nikai E, Yang FE, Gordon KB. Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical Trials. JAMA Dermatol. 2016 Jun 1;152(6):661-9. doi: 10.1001/jamadermatol.2016.0269. PubMed 26953848 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2011 to primary completion in Jun 2014, 31 months.

Results were first posted in May 2016, 1 year 11 months after primary completion. A results delay was requested in Sep 2014.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 31 months is above that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2011
First posted
Nov 18, 2011
StartActual
Nov 16, 2011
Primary completionActual
Jun 24, 2014
CompletionActual
Sep 20, 2018
Results delay requested
Sep 29, 2014
Results first posted
May 27, 2016
Last update
Oct 3, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01474512
Responsible party
Sponsor
First posted
Nov 18, 2011
Start date
Nov 16, 2011
Primary completion
Jun 24, 2014
Completion
Sep 20, 2018
Results posted
May 27, 2016
Last update
Oct 3, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ixekizumab

Start the discussion